Emergent Biosolutions (EBS) Stock
Specialty biopharmaceutical company producing vaccines and public health products. Here's the price, business snapshot, and what's worth knowing about Emergent Biosolutions in June 2026.
Emergent BioSolutions Inc (EBS) is a specialty biopharmaceutical company focused on public‑health countermeasures, including vaccines, therapeutics and related devices. The business mixes commercial products with government and public‑health contracts, and also offers contract manufacturing capacity — a model that can generate steady, often large-scale orders but can make revenue lumpy. With a market capitalisation of about $504.17M, EBS sits in the small‑cap space where operational setbacks or contract timing can have an outsized impact on the share price. Key investor considerations include the company’s exposure to government procurement cycles, regulatory scrutiny of manufacturing quality, and any product concentration or litigation. While a capable manufacturing footprint and specialist product portfolio can be attractive, execution risk and policy dependence are material. This summary is for educational purposes only and is not personal financial advice; suitability depends on your circumstances and you should seek independent advice if unsure.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Emergent BioSolutions' stock, expecting it to rise to $13.5.
Financial Health
Emergent BioSolutions is performing well with solid profits, strong cash flow, and healthy revenue.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring EBS
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: 5 August 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: 1 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Government Contracts
A significant portion of revenue comes from government and public‑health contracts, which can provide scale but be lumpy and sensitive to policy decisions.
Products for Public Health
The company focuses on vaccines, therapeutics and devices for emergencies and infectious diseases — an area with enduring demand, though regulatory hurdles matter.
Manufacturing Risk & Reward
In‑house manufacturing can be a competitive advantage but brings operational and quality risks; past execution issues show how production affects value.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
